Skip to content

post

Combo Of RT And Chemotherapy: Best For Early FL

    For the management of early-stage follicular lymphoma (FL), a randomized trial shows that the combination of radiotherapy (RT) with chemo immunotherapy gives better clinical outcomes that treatment with radiation alone, and the researchers reporting these results say that they should change clinical practice. After a median follow-up of 9.6 years, the estimated 10-year progression-free survival… Read More »Combo Of RT And Chemotherapy: Best For Early FL

    Drug Combination Shows Promise In Advanced Prostrate Cancer.

      Adding the poly ADP ribose polymerase (PARP) inhibitor olaparib (Lynparza, AstraZeneca) to the androgen synthesis inhibitor abiraterone acetate (Zytiga, Janssen) significantly improves progression-free survival (PFS) in men with advanced prostate cancer over abiraterone alone, UK researchers have discovered. Studying 142 patients with metastatic castration-resistant prostate cancer (mCRPC), Dr Noel Clarke, The Christie and Salford Royal… Read More »Drug Combination Shows Promise In Advanced Prostrate Cancer.

      Next-Gen Sequencing for Lung Cancer: Do It Early, for All of Your Patients

        Next-Gen Sequencing for Lung Cancer: Do It Early, for All of Your Patients   Author: Mark G. Kris, MD Mark Kris from Memorial Sloan Kettering in New York City, talking, once again, about the benefits of doing next-generation sequencing (NGS) at diagnosis on persons with lung cancer. We’ve talked before about the need to get this… Read More »Next-Gen Sequencing for Lung Cancer: Do It Early, for All of Your Patients

        Uveal Melanoma: Better Survival With Liver Directed Therapy.

            For patients with uveal melanoma, the most common eye cancer in adults, survival outcomes have improved in recent years, after treatment modalities shifted from systemic to liver-directed therapies. The finding comes from researchers at the Thomas Jefferson University in Philadelphia, Pennsylvania, and was presented at the recent American Society of Clinical Oncology (ASCO) 2018… Read More »Uveal Melanoma: Better Survival With Liver Directed Therapy.

          FDA Approves Pegfilgrastim Biosimilar for Cancer Infection Risk

            Author: Nick Mulcahy The U.S. Food and Drug Administration has approved the first biosimilar to pegfilgrastim (Neulasta, Amgen), a granulocyte colony-stimulating factor used to reduce infection risk in patients with cancer. The new product is pegfilgrastim-jmdb ( Fulphila , Mylan GmbH), approved for use to decrease the risk for infection in patients with nonmyeloid cancer who are receiving… Read More »FDA Approves Pegfilgrastim Biosimilar for Cancer Infection Risk

            ‘Oncology Done Right Is About Balance’: Weighing Immunotherapy Side Effects

              Author: Mark G. Kris, MD Hello. This is Mark Kris from Memorial Sloan Kettering. I am speaking to you today about three papers that appeared in JAMA Oncology on January 11, 2018, dealing with the adverse effects of immune checkpoint inhibitors. There was a commentary and two papers. My issue with these presentations is the lack of discussion of benefits… Read More »‘Oncology Done Right Is About Balance’: Weighing Immunotherapy Side Effects

              Risk of Methotrexate Dosing Errors Prompts EMA Review

                Reporter: Megan Brook The European Medicines Agency (EMA) is reviewing the risk of dosing errors with medicines containing methotrexate. The review is based on “continued reports of overdose,” the agency announced today. Methotrexate is used to treat various inflammatory conditions, such as arthritis, psoriasis, and some cancers, such as acute lymphoblastic leukemia. Methotrexate can be taken… Read More »Risk of Methotrexate Dosing Errors Prompts EMA Review